Based on genetic alterations, DLBCL can be subdivided into distinct subgroups using LymphGen algorithm or other: MCD (MYD88L265P and CD79B mutations), N1 (NOTCH1 mutation), A53 (aneuploidy with TP53 inactivation), BN2 (BCL6 translocation and NOTCH2 mutation), ST2 (SGK1 and TET2 mutated) and EZB (EZH2 mutation and BCL2 translocation), with the latter subgroup further divided into EZB-MYC+ and EZB-MYC- according to MYC signature [3, 4]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.